Shandong Xinbo is a scientific research service enterprise integrating pharmacodynamic research, toxicological research, drug analysis and testing services, animal pathology testing, and medical device evaluation services. It is a high-tech enterprise and a Shandong Provincial Enterprise Technology Center.

Shandong Xinbo has established Jinan Laboratory and Linyi Laboratory. Currently, it has built nearly 20,000 square meters of pharmacology and toxicology research laboratories that meet international standards, equipped with over 800 advanced instruments and equipment from both domestic and international sources. The toxicology research laboratory is capable of conducting single-dose toxicity tests, repeated-dose toxicity tests, safety pharmacology tests, reproductive toxicity tests, genetic toxicity tests, local toxicity tests, immunogenicity tests, and toxicokinetic tests in accordance with the GLP standards of NMPA and FDA.

The company is dedicated to providing high-quality commissioned research services for new drug and medical research institutions. Since its establishment in 2010, it has provided over 12,000 services to more than 620 pharmaceutical companies, new drug research institutions, and research institutes both domestically and internationally. It has completed nearly 550 preclinical evaluation services for innovative drugs in accordance with domestic and international regulatory requirements, including small molecule drugs, biological macromolecule drugs, new preventive and therapeutic vaccines, and traditional Chinese medicine/natural medicine evaluations. It has assisted research and development units in obtaining over 100 clinical approvals for new drugs, and has accumulated rich experience in the evaluation of therapeutic vaccines, cell and gene therapy drugs, which have developed rapidly in recent years. It has also completed the evaluation of nearly 4,800 generic drug varieties.

In addition, the company continuously innovates and practices, breaks through barriers, and has made improvements and explorations in areas such as challenging administration techniques for young animals, continuous intravenous administration techniques, and tracheal administration techniques. These advancements have been maturely applied to safety evaluations. The company also pays attention to the needs of innovative development in the global pharmaceutical industry, focuses on the key links of innovative drug research and development, and leverages the experience accumulated from serving the domestic and international pharmaceutical industry to provide comprehensive preclinical research and development services for new drugs to the global pharmaceutical industry.